
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm Therapeutics develops therapeutic drug products based on an innovative drug delivery technology that has the potential to improve drug efficacy and safety in open label settings. Its lead product candidate, KPT-8602 for solid tumors and KPT-1203 for hematological malignancies, uses its proprietary Permeation Enhancing Sequence (PES)-based lipophilic doxorubicin (DOX) prodrug platform to develop novel therapeutics with potential clinical and commercial applications. Karyopharm Therapeutics is also developing KRN2300 to treat patients with multiple myeloma.
Latest events on Quartr
Previous Events for Karyopharm Therapeutics Inc
Ticker
KPTI
Country
United States of America